Pharmacological profile of the selective mitochondrial F1F0 ATP hydrolase inhibitor BMS-199264 in myocardial ischemia.

@article{Grover2008PharmacologicalPO,
  title={Pharmacological profile of the selective mitochondrial F1F0 ATP hydrolase inhibitor BMS-199264 in myocardial ischemia.},
  author={Gary James Grover and Johan Malm},
  journal={Cardiovascular therapeutics},
  year={2008},
  volume={26 4},
  pages={
          287-96
        }
}
The mitochondrial F1F0 ATP synthase is responsible for the majority of ATP production in mammals and does this through a rotary catalytic mechanism. Studies show that the F1F0 ATP synthase can switch to an ATP hydrolase, and this occurs under conditions seen during myocardial ischemia. This ATP hydrolysis causes wasting of ATP that does not produce work. The degree of ATP inefficiently hydrolyzed during ischemia may be as high as 50-90% of the total. A naturally occurring, reversible inhibitor… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Mitochondria as ATP consumers in cellular pathology.

  • Biochimica et biophysica acta
  • 2010
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

NADH as a cancer medicine

VIEW 1 EXCERPT
CITES BACKGROUND

Regulation of mitochondrial ATP synthase in cardiac pathophysiology.

  • American journal of cardiovascular disease
  • 2015
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

Effect of inhibition of the mitochondrial ATPase on net myocardial 294 Cardiovascular Therapeutics

RB Jennings, KA Reimer, C. Steenbergen
  • The Authors. Journal Compilation c © 2008 Blackwell Publishing Ltd G. J. Grover and J. Malm F1F0 Hydrolase Inhibitor
  • 2008

Structures and interactions of proteins involved in the coupling function of the Cardiovascular Therapeutics

A Gaballo, F Zanotti, S. Papa
  • J. Grover and J. Malm proton motive F0F1-ATP synthase. Curr Protein Pept Sci 2000;3:451–460
  • 2008
VIEW 1 EXCERPT